To the Editor.
—We read with interest the article by Oseï et al1 in the October 1986 issue of the Archives. The authors performed an open study on 13 hypertensive diabetic patients to assess the effects of a 24-week administration of indapamide on blood pressure, glucose, and lipid metabolism. Their results led them to conclude that indapamide may give rise to unfavorable glucose and lipid tolerance in such patients. However, a review of the article raises several questions concerning its methodology.First, of concern is the population included in the study. The small number of patients studied, together with the widely varying characteristics of their diabetes, make the group quite heterogeneous as regards the possible effects of any drugs. For example, the duration of diabetes ranged from 0 to 19 years, fasting serum glucose from 4.5 to 15.6 mmol/L,1 and HbA1 from 5% to 15.7%. In addition,
Guez D, Brackman F. Indapamide in the Diabetic Hypertensive. Arch Intern Med. 1988;148(9):2073–2077. doi:10.1001/archinte.1988.00380090129031
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: